Right ovarian serous cystadenocarcinoma and left ovarian mature cystic teratoma

Aims: The aim of this study was to evaluate the incidence of neoplastic as well as non-neoplastic ovarian lesions and to find out the frequency and age distribution of benign and malignant ovarian neoplasms.Methods: A retrospective cross sectional study on a series of cases was performed in the Department of Pathology, Patan Academy of Health Sciences, Patan Hospital, Lalitpur, Nepal from April 2011 to March 2016. Data from the histopathology database were analyzed using SPSS version 16.0.Results: During the study period, surgical specimens of 528 ovarian masses were received at our institution. Among them, 399 cases (76%) were neoplasms and 129 cases (24%) were non-neoplastic lesions. Benign, borderline and malignant neoplasms were 89.7%, 1.8% and 8.5% respectively. Benign neoplasms were more common in 21-30 years and malignant in 41-50 years age group. There were 156 (39.1%) surface epithelial tumors, 236 (59.1%) germ cells tumors and 6 (1.5%) sex cord stromal tumors. Mature cystic teratoma, followed by serous cystadenoma was the most frequently encountered benign tumor. Serous cystadenocarcinoma was most prevalent in the malignant group. Among the non-neoplastic masses, the most common was endometriotic cyst (55%) followed by corpus luteal cyst (29%).Conclusions: Ovarian neoplasms are more common than non-neoplastic lesions. Malignant tumors affect older women more frequently than younger women. Mature cystic teratoma was the most frequently encountered benign tumor. Serous cystadenocarcinoma was most prevalent in the malignant group. Endometriotic cyst was the most common non-neoplastic lesion.

Download Full-text

A Case Report: Mature cystic teratoma of the Pouch of Douglas managed laparoscopically in a 25 – year – old Nulligravid

10.26226/morressier.5770e29dd462b80290b4c30a ◽

2016 ◽

Author(s):

Dioselle Camia - Hussin

Keyword(s):

Case Report ◽

Cystic Teratoma ◽

Mature Cystic Teratoma ◽

Pouch Of Douglas

Download Full-text

Presacral mature cystic teratoma: Part of Currarino triad

10.26226/morressier.578f37fbd462b8028d8901de ◽

2016 ◽

Author(s):

Luis Mascarenhas-Lemos

Keyword(s):

Cystic Teratoma ◽

Mature Cystic Teratoma

Download Full-text

How Do You Distinguish The Malignant Change Of Mature Cystic Teratoma And Immature Teratoma Of Ovary?

10.26226/morressier.59f838b6a874c6001b34ea19 ◽

2017 ◽

Author(s):

Kyongjin Kim

Keyword(s):

Cystic Teratoma ◽

Immature Teratoma ◽

Mature Cystic Teratoma ◽

Malignant Change

Download Full-text

Ovarian mature cystic teratoma with malignant transformation: two case reports

Journal of Medical Case Reports ◽

10.1186/s13256-020-02594-4 ◽

2021 ◽

Vol 15 (1) ◽

Author(s):

Afsaneh Tehranian ◽

Akram Ghahghaei-Nezamabadi ◽

Akram Seifollahi ◽

Sara Kasraei ◽

Hamideh Dehghani-Nejad ◽

...

Keyword(s):

Malignant Transformation ◽

Case Reports ◽

Cystic Teratoma ◽

Good Prognosis ◽

Mature Cystic Teratoma ◽

Treatment Protocols ◽

Large Size ◽

Stage Ia ◽

Loss Of Appetite ◽

Case Number

Abstract Background Mature Cystic Teratoma (MCT) is a benign tumor that can lead to malignant transformation (MT) in 1–3% of cases. Management of MT is a big challenge for gynecologic oncologists due to the lack of specific diagnostic and treatment protocols. Case presentation We reported two Iranian cases of MT of MCT with two different stages and prognosis. Our both cases presented the same symptoms, including chronic abdominal pain and distention, loss of appetite, and weight loss. In case number 1, despite the large size of the tumor, the disease was at stage Ia and had a good prognosis; while, case number 2 was at stage IIIc of the disease with a poor prognosis. Conclusion The stage of the disease is the most important prognostic factor, and early diagnosis and treatment are very critical for better survival.

Download Full-text

Genetic Profiling of Malignant Melanoma Arising from an Ovarian Mature Cystic Teratoma: A Case Report

International Journal of Molecular Sciences ◽

10.3390/ijms22052436 ◽

2021 ◽

Vol 22 (5) ◽

pp. 2436

Author(s):

Kohei Nakamura ◽

Eriko Aimono ◽

Reika Takamatsu ◽

Shigeki Tanishima ◽

Tomonari Tohyama ◽

...

Keyword(s):

Malignant Melanoma ◽

Malignant Tumors ◽

Cystic Teratoma ◽

Homozygous Deletion ◽

Mature Cystic Teratoma ◽

Genetic Profiling ◽

Improve Treatment ◽

The Status ◽

Genetic Mechanisms ◽

Targeted Gene Sequencing

Ovarian mature cystic teratomas comprise tissues derived from all three germ layers. In rare cases, malignant tumors arise from ovarian mature cystic teratoma. A variety of tumors can arise from mature cystic teratoma, among which primary malignant melanoma (MM), for which no molecular analyses such as genomic sequencing have been reported to date, is exceedingly rare, thereby limiting possible therapeutic options using precision medicine. We used targeted gene sequencing to analyze the status of 160 cancer-related genes in a patient with MM arising from an ovarian mature cystic teratoma (MM-MCT). KRAS amplification and homozygous deletion in PTEN and RB1 were detected in tumor samples collected from the patient. No KRAS amplification has been previously reported in cutaneous MM, indicating that the carcinogenesis of MM-MCT differs from that of primary cutaneous melanomas. A better understanding of the underlying genetic mechanisms will help clarify the carcinogenesis of MM-MCT. In turn, this will enable treatment with novel targeting agents as well as the initial exploration of gene-based precision oncological therapies, which aim to improve treatment outcomes for patients with this disease.

Download Full-text